Recent Insights into Serum Free Light Chain Assays for Plasma Cell Disorders

Featured Speakers and Topics

Dr. Maria Willrich will discuss “Recent Studies of sFLC Assays and Their Impact on Clinical Assessment”

Dr. Angela Dispenzieri will discuss “The Importance of Testing for Monoclonal Proteins in Non-Tissue Diagnosis of Cardiac Amyloidosis”

Abstract
Serum free light chain (sFLC) tests have advanced the prediction, diagnosis, and monitoring of plasma cell disorders. This webinar features two leading experts who will compare the performance of sFLC assays in the contexts of Multiple Myeloma, including its precursors such as MGUS and smoldering myeloma, and Amyloidosis. With the introduction of updated guidelines for monoclonal gammopathies and a new, 2023 consensus for cardiac amyloidosis, attendees will gain valuable insights into the interchangeability of assay platforms and key considerations for optimizing testing triage. The discussion will also address reference intervals, method selection, and strategies to enhance assay specificity for improved testing accuracy.

Learning Objectives

• Describe the use of sFLC assays in diagnosing and managing plasma cell disorders.
• Discuss efforts to standardize sFLC assays across platforms and reference intervals with clinical implications.
• Identify the role of monoclonal proteins, especially sFLC, with regards to the 2023 American College of Cardiology Expert Consensus on Cardiac Amyloidosis.